Capecitabine, DNA/RNA Synthesis Inhibitor

Por um escritor misterioso
Last updated 01 fevereiro 2025
Capecitabine, DNA/RNA Synthesis Inhibitor
Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase. - Mechanism of Action & Protocol.
Capecitabine, DNA/RNA Synthesis Inhibitor
Nucleoside analogues and nucleobases in cancer treatment - The Lancet Oncology
Capecitabine, DNA/RNA Synthesis Inhibitor
APExBIO - Capecitabine
Capecitabine, DNA/RNA Synthesis Inhibitor
Interference with Nucleic Acid Synthesis - Creative Biolabs
Capecitabine, DNA/RNA Synthesis Inhibitor
Mapping combinatorial drug effects to DNA damage response kinase inhibitors
Capecitabine, DNA/RNA Synthesis Inhibitor
Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer
Capecitabine, DNA/RNA Synthesis Inhibitor
Capecitabine, DNA/RNA Synthesis Inhibitor
Capecitabine, DNA/RNA Synthesis Inhibitor
5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review)
Capecitabine, DNA/RNA Synthesis Inhibitor
Cancers, Free Full-Text
Capecitabine, DNA/RNA Synthesis Inhibitor
Gemcitabine (LY 188011), DNA Synthesis Inhibitor
Capecitabine, DNA/RNA Synthesis Inhibitor
Anti-Cancer Drugs-Medicinal Chemistry
Capecitabine, DNA/RNA Synthesis Inhibitor
View of Genetic factors affecting patient responses to pancreatic cancer treatment
Capecitabine, DNA/RNA Synthesis Inhibitor
Frontiers PARP inhibitors combined with radiotherapy: are we ready?
Capecitabine, DNA/RNA Synthesis Inhibitor
Full article: Facile construction of dual-drug loaded nanoparticles for improvement synergistic chemotherapy in prostate cancer
Capecitabine, DNA/RNA Synthesis Inhibitor
Metabolic conversion of capecitabine to 5-fluorouracil
Capecitabine, DNA/RNA Synthesis Inhibitor
5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition - ScienceDirect

© 2014-2025 phtarkwa.com. All rights reserved.